Here are four things to know.
1. The Partnership for Accelerating Cancer Therapies is part of the Cancer Moonshot program launched under the Obama administration.
2. Through the $215 million initiative, researchers will study chemical signatures in the body that help identify patients who will benefit from cancer immunotherapy.
3. Participating drugmakers include AbbVie, Roche, Bristol-Myers Squibb, Pfizer, Johnson & Johnson, Amgen, Celgene Corp., Gilead Sciences and GlaxoSmithKline. Merck, which sells the popular cancer immunotherapy Keytruda, is not involved with the initiative.
4. Drug companies will contribute $55 million to the research initiative, and NIH will provide the remaining $160 million, based on the availability of funds.
More articles on data analytics & precision medicine:
8 things to know about gene-editing tech CRISPR
Louisiana State U, Moffitt Cancer Center partner to address racial disparities in precision medicine
Survey: Healthcare execs name data analytics, population health among top challenges for 2018
